Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS), which worsen patients’ health and increase healthcare spending. The aim of this study was to assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Carpagnano, Giovanna Elisiana, Resta, Emanuela, Povero, Massimiliano, Pelaia, Corrado, D’Amato, Mariella, Crimi, Nunzio, Scichilone, Nicola, Scioscia, Giulia, Resta, Onofrio, Calabrese, Cecilia, Pelaia, Girolamo, Barbaro, Maria Pia Foschino
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7943587/
https://ncbi.nlm.nih.gov/pubmed/33750842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-84895-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi